Reimb of renal anemia drug in progress upon FDA approval
By Nho, Byung Chul | translator Kim, Jung-Ju
24.03.29 06:00:09
가나다라
0
Mitsubishi Tanabe Pharma’s Vadanem receives US FDA approval this month… will soon receive pricing in Europe
JW Pharmaceutical’s Enaroy also soon expected to start drug pricing negotiations
Injectables dominate KRW 100 billion renal anemia drug market..."Release of tablets expand treatment options for the patients and reduce healthcare costs.”
As Korea’s health authorities were eyeing whether to start pricing negotiations for Mitsubishi Tanabe Pharma’s Vadanem based on the FDA’s approval decision in the U.S. and pricing decision in Europe, the FDA approval is expected to accelerate the drug’s negotiation process in Korea.
According to industry sources, Vadanem was approved by the FDA on the 27th and is expected to receive pricing in Europe as early as April.
Vadanem already received approval from the Ministry of Food and Drug Safety last year. The same year, the company applied for US approval of t
Nho, Byung Chul(sasiman@dailypharm.com)
If you want to see the full article, please JOIN US (click)